Become a donor or member and support our work to advance access to medicines. For everyone. Everywhere
Media Resources
2013
Comprendre la promotion pharmaceutique et y répondre: Un manuel pratique
EU-India free trade deal puts millions of lives at risk
2012 Annual Report
2012 Financial Statements
2012
ACTA is dead, long live ACTA? ACTA-like measures still in EU IP policies
Time for the final push: Say “No” to ACTA – again
EU Parliament Says No and No Again to EMA: Independent Groups Echo Decision
Big Pharma Spends Over €40 Million per Year Lobbying in the EU, Dwarfing Public Health NGOs
Civil Society Calls on Members of the European Parliament to Condemn ACTA
Divide and Conquer: A look behind the scenes of the EU pharmaceutical industry lobby
Business Conduct Guidelines
Complaints Procedure (EN)
Unlocking the Mysteries of Access to Clinical Trials Data in the EU
2011
Statement on Medicines Patent Pool
Universal Access to Medicines for Non-Communicable Diseases
Drop in Pay-for-Delay Good for Access to Medicines in Europe
Statement on Conflicts of Interests delivered at WHA
Statement on EU India and EU Mercosur Free-Trade Negotiations
Medicines pay-for-delay back under the microscope
2010
EU Citizens Get a Voice in Pharmacovigilance
Understanding & Responding to Pharmaceutical Promotion: A Practical Guide
2009
Unbiased medicines’ information: European best practices
Wyzwanie dla niezależnej informacji: dyrektywa w sprawie informowania pacjentów
Understanding and Responding to Pharmaceutical Promotion: A Practical Guide
The Tide is Turning Against Pharmaceutical Ads
Protect Legitimate Trade in Essential Medicines
HAI Requests Government Documents on Generic Medicines Seizures
Release of Generic ARV Medicines by Dutch Customs Authorities
2007